X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
SC-2882 is a Scenic’s first-in-class QPCTL inhibitor, it is curently in preclinical stage where it is being evaluated as a new potential treatment approach for diffuse large B-cell lymphoma (DLBCL).
Lead Product(s): SC-2882
Therapeutic Area: Oncology Product Name: SC-2882
Highest Development Status: PreclinicalProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 09, 2023
Details:
CRADA combines Scenic Biotech’s genetic modifier platform with NIH’s patient registry to unlock genetic modifiers as a path to novel therapies for NPC disease. The goal of the collaboration is to obtain clinical insights into genes that can reduce the severity of NPC.
Lead Product(s): Undisclosed
Therapeutic Area: Rare Diseases and Disorders Product Name: Undisclosed
Highest Development Status: DiscoveryProduct Type: Small molecule
Partner/Sponsor/Collaborator: NICHD
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Agreement February 01, 2023
Details:
Both companies, aim to identify small molecule drugs to treat Niemann Pick Type C (NP-C), a rare lipid storage disorder that affects lipid metabolism, a second undisclosed program to treat a severe heritable metabolic syndrome, and Barth syndrome program.
Lead Product(s): Undisclosed
Therapeutic Area: Genetic Disease Product Name: Undisclosed
Highest Development Status: DiscoveryProduct Type: Small molecule
Partner/Sponsor/Collaborator: Barth Syndrome Foundation
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Partnership March 30, 2022
Details:
Under the terms of the agreement, Scenic will utilize its Cell-Seq platform and its data warehouse of genetic modifiers to identify drug targets in multiple therapeutic areas.
Lead Product(s): Undisclosed
Therapeutic Area: Genetic Disease Product Name: Undisclosed
Highest Development Status: DiscoveryProduct Type: Undisclosed
Partner/Sponsor/Collaborator: Genentech
Deal Size: $375.0 million Upfront Cash: Undisclosed
Deal Type: Collaboration September 21, 2020
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
